Clinical Trials Browser

Phase 1/2 × OTHER × glofitamab × Clear all

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Mantle-Cell

NCT06357676 2026-01-30

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Phase 1/2 Recruiting

Lymphoma, Mantle-Cell

NCT04914741 2024-08-12

COALITION

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse